465 related articles for article (PubMed ID: 20142601)
21. Cognitive functioning during long-term tamoxifen treatment in postmenopausal women with breast cancer.
Boele FW; Schilder CM; de Roode ML; Deijen JB; Schagen SB
Menopause; 2015 Jan; 22(1):17-25. PubMed ID: 24977455
[TBL] [Abstract][Full Text] [Related]
22. Exemestane or tamoxifen?
Ueda M; Toji E; Noda S
Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
[No Abstract] [Full Text] [Related]
23. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
[TBL] [Abstract][Full Text] [Related]
24. [Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Nagykálnai T
Magy Onkol; 2008 Jun; 52(2):133-43. PubMed ID: 18640889
[TBL] [Abstract][Full Text] [Related]
25. Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents.
Mortimer JE; Urban JH
Oncology (Williston Park); 2003 May; 17(5):652-9; discussion 659, 662, 666 passim. PubMed ID: 12800793
[TBL] [Abstract][Full Text] [Related]
26. Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy.
Hadji P; Kauka A; Bauer T; Tams J; Hasenburg A; Kieback DG
Climacteric; 2012 Oct; 15(5):460-6. PubMed ID: 22321061
[TBL] [Abstract][Full Text] [Related]
27. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.
Francini G; Petrioli R; Montagnani A; Cadirni A; Campagna S; Francini E; Gonnelli S
Br J Cancer; 2006 Jul; 95(2):153-8. PubMed ID: 16835585
[TBL] [Abstract][Full Text] [Related]
28. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
[TBL] [Abstract][Full Text] [Related]
29. Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis.
van Nes JG; Beex LV; Seynaeve C; Putter H; Sramek A; Lardenoije S; Duijm-de Carpentier M; Van Rongen I; Nortier JW; Zonderland HM; van de Velde CJ
Acta Oncol; 2015 Mar; 54(3):349-60. PubMed ID: 25383451
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.
Fontein DB; Charehbili A; Nortier JW; Meershoek-Klein Kranenbarg E; Kroep JR; Putter H; van Riet Y; Nieuwenhuijzen GA; de Valk B; Terwogt JM; Algie GD; Liefers GJ; Linn S; van de Velde CJ
Eur J Cancer; 2014 Sep; 50(13):2190-200. PubMed ID: 24970786
[TBL] [Abstract][Full Text] [Related]
31. Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study.
van Nes JG; Fontein DB; Hille ET; Voskuil DW; van Leeuwen FE; de Haes JC; Putter H; Seynaeve C; Nortier JW; van de Velde CJ
Breast Cancer Res Treat; 2012 Jul; 134(1):267-76. PubMed ID: 22453754
[TBL] [Abstract][Full Text] [Related]
32. Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
van Hezewijk M; Bastiaannet E; Putter H; Scholten AN; Liefers GJ; Rea D; Hasenburg A; Paridaens R; Hozumi Y; Markopoulos C; Seynaeve C; Jones SE; Marijnen CA; van de Velde CJ
Radiother Oncol; 2013 Aug; 108(2):190-6. PubMed ID: 24044798
[TBL] [Abstract][Full Text] [Related]
33. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Conte P; Frassoldati A
Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
[TBL] [Abstract][Full Text] [Related]
34. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
Aihara T; Suemasu K; Takei H; Hozumi Y; Takehara M; Saito T; Ohsumi S; Masuda N; Ohashi Y
Oncology; 2010; 79(5-6):376-81. PubMed ID: 21430407
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
Derks MGM; Blok EJ; Seynaeve C; Nortier JWR; Kranenbarg EM; Liefers GJ; Putter H; Kroep JR; Rea D; Hasenburg A; Markopoulos C; Paridaens R; Smeets JBE; Dirix LY; van de Velde CJH
Lancet Oncol; 2017 Sep; 18(9):1211-1220. PubMed ID: 28732650
[TBL] [Abstract][Full Text] [Related]
36. Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Breast Cancer Res Treat; 2009 Jan; 113(2):321-6. PubMed ID: 18297393
[TBL] [Abstract][Full Text] [Related]
37. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer.
Bender CM; Sereika SM; Brufsky AM; Ryan CM; Vogel VG; Rastogi P; Cohen SM; Casillo FE; Berga SL
Menopause; 2007; 14(6):995-8. PubMed ID: 17898668
[TBL] [Abstract][Full Text] [Related]
38. Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors.
Schilder CM; Seynaeve C; Linn SC; Boogerd W; Beex LV; Gundy CM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
Crit Rev Oncol Hematol; 2010 Nov; 76(2):133-41. PubMed ID: 20036141
[TBL] [Abstract][Full Text] [Related]
39. Compliance, analgesic use and side-effect protection within a German cohort of the TEAM trial.
Bossart M; Becker M; Hadji P; Kieback DG; Hasenburg A
Anticancer Res; 2012 Sep; 32(9):3933-8. PubMed ID: 22993340
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.
van de Velde CJ; Rea D; Seynaeve C; Putter H; Hasenburg A; Vannetzel JM; Paridaens R; Markopoulos C; Hozumi Y; Hille ET; Kieback DG; Asmar L; Smeets J; Nortier JW; Hadji P; Bartlett JM; Jones SE
Lancet; 2011 Jan; 377(9762):321-31. PubMed ID: 21247627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]